Literature DB >> 9041214

Dialysate sodium delivery can alter chronic blood pressure management.

M J Flanigan1, Q T Khairullah, V S Lim.   

Abstract

Low dialysate sodium concentrations can reduce postdialysis thirst and serum sodium activity, but patients typically experience dialysis hypotension, fatigue, disequilibrium, and cramps. "High-sodium" hemodialysis minimizes dialysis disequilibrium but increases the serum sodium activity of most patients. Programmed "variable-sodium" dialysis can minimize dialysis discomfort but may also alter the sodium kinetics from those of "high-sodium" dialysis. We designed a cross-over study with random order assignment to determine whether a "variable-sodium" dialysis program could reduce the blood pressure of dialysis patients without increasing dialysis morbidity. Dialysis with a dialysate sodium of 140 mEq/L was compared with dialysis with a programmed exponential decrease of dialysate sodium from 155 mEq/L to 135 mEq/L. Dialysate sodium was then held constant at 135 mEq/L for the final half hour of dialysis. Eighteen patients completed the 7-month study, each receiving 3.5 months of experimental and 3.5 months of standard therapy. Programmed "variable-sodium" dialysis resulted in a reduction in antihypertensive drug use without alterations in predialysis blood pressure, interdialytic weight gain, ultrafiltration tolerance, or the frequency of symptomatic dialysis cramps or hypotension. Patients did, however, have lower postdialysis standing blood pressures and higher postdialysis target weights during programmed "variable-sodium" dialysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041214     DOI: 10.1016/s0272-6386(97)90199-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

Review 1.  Optimal dialysate sodium-what is the evidence?

Authors:  Finnian R Mc Causland; Sushrut S Waikar
Journal:  Semin Dial       Date:  2014-01-23       Impact factor: 3.455

2.  Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters.

Authors:  Johan M Lorenzen; Thomas Thum; Georg M Eisenbach; Hermann Haller; Jan T Kielstein
Journal:  Int Urol Nephrol       Date:  2011-02-27       Impact factor: 2.370

Review 3.  Dialysate Sodium: Rationale for Evolution over Time.

Authors:  Jennifer E Flythe; Finnian R Mc Causland
Journal:  Semin Dial       Date:  2017-01-08       Impact factor: 3.455

Review 4.  Hypertension in hemodialysis patients.

Authors:  M Rahman; M C Smith
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study.

Authors:  Jair Munoz Mendoza; Liz Y Bayes; Sumi Sun; Sheila Doss; Brigitte Schiller
Journal:  Am J Kidney Dis       Date:  2011-08-27       Impact factor: 8.860

Review 6.  Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.

Authors:  Panagiotis I Georgianos; Rajiv Agarwal
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 7.  Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis.

Authors:  Jula K Inrig
Journal:  Am J Kidney Dis       Date:  2009-10-22       Impact factor: 8.860

8.  Blood-volume monitoring in paediatric haemodialysis.

Authors:  Daljit K Hothi; Elizabeth Harvey; Christina M Goia; Denis Geary
Journal:  Pediatr Nephrol       Date:  2008-01-26       Impact factor: 3.714

9.  Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.

Authors:  Rajiv Agarwal; Pooneh Alborzi; Sangeetha Satyan; Robert P Light
Journal:  Hypertension       Date:  2009-01-19       Impact factor: 10.190

Review 10.  Hypertension in dialysis and kidney transplant patients.

Authors:  G V Ramesh Prasad; Marcel Ruzicka; Kevin D Burns; Sheldon W Tobe; Marcel Lebel
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.